Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255086 · ClinicalTrials.gov registry record · Phase 3
The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients
A Phase 3 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 3
- Development phase
- 17
- Enrollment target
NCT00255086: Completed Phase 3 study, sponsored by Stanford University.
NCT00255086 is a Phase 3 study that has completed, run by Stanford University. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00255086, a Phase 3 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 17 participants
- Enrollment target
Study Summary
The aim of the proposed study is to determine if the NMDA receptor antagonist memantine has a neuroprotective effect on magnetic resonance spectroscopic imaging (MRS) measures of brain NAA and magnetic resonance imaging (MRI) volumetric measures of hippocampal volume. In secondary analyses, we will determine if measures of clinical stabilization produced by memantine in the treatment of Alzheimer's disease (AD) parallels stabilization of MRS measures of brain NAA and MRI volumetric measures of hippocampal volume.
Interventions
- DRUG Placebo pill
- DRUG Memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2005-05 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00255086
The ClinicalTrials.gov registry entry for NCT00255086 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo pill is the first listed.
NCT00255086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00255086 about?
NCT00255086 is a clinical study titled "The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients". The aim of the proposed study is to determine if the NMDA receptor antagonist memantine has a neuroprotective effect on magnetic resonance spectroscopic imaging (MRS) measures of brain NAA and magnetic resonance imaging (MRI) volumetric measures of hippocampal volume. In secondary analyses, we will ...
What is the current status of trial NCT00255086?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2005-05. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00255086?
The interventions under investigation include: Placebo pill (DRUG), Memantine (DRUG).
Who is sponsoring clinical trial NCT00255086?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.